Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) ended Friday session in red amid volatile trading. The shares closed down -0.66 points or -6.16% at $10.06 with 1.50 million shares getting traded. Post opening the session at $10.48, the shares hit an intraday low of $10.04 and an intraday high of $10.65 and the price vacillated in this range throughout the day. The company has a market cap of $1.22 billion and the numbers of outstanding shares have been calculated to be 129.41 million shares.
Halozyme Therapeutics, Inc. (HALO) announced that it will be presenting at the Bank of America Merrill Lynch 2016 Global Health Care Conference in London, on Thurs., Sept. 15 at 11:25 a.m. BST/6:25 a.m. EDT/3:25 a.m. PDT. Dr. Helen Torley, president and CEO, will provide a corporate overview.
The sessions will be webcast through the “Investors” section of Halozyme’s corporate website at www.halozyme.com, and a recording will be made available for 90 days following each event. To access the live webcast, please log on to Halozyme’s website approximately 15 minutes early to register and download any necessary audio software.
Shares of Edwards Lifesciences Corp (NYSE:EW) ended Friday session in red amid volatile trading. The shares closed down -2.73 points or -2.33% at $114.60 with 1,477,590 shares getting traded. Post opening the session at $116.63, the shares hit an intraday low of $114.58 and an intraday high of $117.00 and the price vacillated in this range throughout the day. The company has a market cap of $23.83 billion and the numbers of outstanding shares have been calculated to be 212.88 million shares.
Edwards Lifesciences Corp (EW) on Aug. 18, 2016 announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis who have been determined by a Heart Team to be at intermediate risk for open-heart surgery. The SAPIEN 3 valve is the first transcatheter aortic valve replacement (TAVR) therapy to obtain this indication in the United States.
“The SAPIEN 3 valve has set a new standard for performance and patient outcomes with aortic valve replacement,” said Vinod Thourani, M.D., co-director of Emory Heart and Vascular Center’s Structural Heart and Valve Center and professor of cardiothoracic surgery at Emory University School of Medicine. “The clinical outcomes of 1.1 percent mortality and 1.0 percent disabling stroke at 30 days in this intermediate-risk population treated with the SAPIEN 3 valve are changing the paradigm of how we treat patients with aortic stenosis.”
Thourani is the co-principal investigator of the SAPIEN 3 valve study.
“The intermediate-risk approval of the SAPIEN 3 valve is a major milestone, since it provides a less-invasive therapy that has demonstrated better outcomes for aortic valve patients, and is supported by the largest and rigorous comparative body of evidence for the treatment of aortic stenosis,” said Larry L. Wood, Edwards’ corporate vice president, transcatheter heart valves.
The SAPIEN 3 valve intermediate-risk approval was based on data from a cohort of the PARTNER II Trial, which studied 2,005 intermediate-risk patients at 51 sites in the United States and Canada. The study demonstrated that patients treated with the SAPIEN 3 valve experienced clinically significant improvements for the composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation at one year as compared to those treated with surgery. The data were presented in April at the American College of Cardiology’s 65th Annual Scientific Session and simultaneously published in The Lancet.
The expanded intermediate-risk indication granted by the FDA enables Heart Teams to treat patients with the SAPIEN 3 valve who they determine to have a predicted risk of surgical mortality of greater than or equal to 3 percent at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator.
The SAPIEN 3 valve builds on Edwards’ decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves. The SAPIEN 3 valve was approved by the FDA in June 2015 for the treatment of patients with severe, symptomatic aortic stenosis who are at high-risk for open heart surgery.